United Kingdom

People: Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

9:00pm BST
Change (% chg)

$-0.10 (-1.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Corash, Laurence 

Dr. Laurence M. Corash, M.D., is Chief Scientific Officer of Cerus Corporation. Dr. Corash is one of our co-founders, has served as a member of our Board since December 2002. As noted above, Dr. Corash announced his intention to not stand for reelection at, and he will retire from the Board effective as of, the Annual Meeting. Dr. Corash has been our Chief Scientific Officer since July 2015, and will continue to serve as our Chief Scientific Officer following his retirement from the Board. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008, Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011, Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability. Dr. Corash’s extensive knowledge of us, having been a director since 2002, brought historic knowledge and continuity to the Board, and his scientific expertise obtained from over 30 years as an M.D. in the field of hematology contributed significantly to the Board.

Basic Compensation

Total Annual Compensation, USD 604,544
Restricted Stock Award, USD 205,200
Long-Term Incentive Plans, USD --
All Other, USD 230,519
Fiscal Year Total, USD 1,040,260

Options Compensation

  Quantity Market Value
Exercisable 281,619 546,323.00
Unexercisable 163,006 910,754.00
Exercised 35,000 122,500.00
Name Fiscal Year Total

Daniel Swisher


William Greenman


Kevin Green


Carol Moore


William Moore


Laurence Corash

As Of  31 Dec 2018